Determining the Ideal Strategy for Ventilator-associated Pneumonia Prevention. Cost–Benefit Analysis

Abstract

Despite their infrequent use, current data suggest that the use of prophylactic probiotics and subglottic endotracheal tubes are cost-effective for preventing VAP from the societal and hospital perspectives.